The uptake of 125I‐antiTLR5 mAb in TLR5+ 4T1 tumours at 24, 48 and 72 hours post‐injection was 7.725 ± 0.7525, 4.9225 ± 0.36 and 2.5775 ± 0.1825 (%ID/g), T/NT ratio of 6.481 ± 0.6023, 8.413 ± 0.5270 and 7.152 ± 1.040, respectively, while the uptake of 125I‐antiTLR5 mAb in TLR5− 4T1 tumours was 2.8225 ± 0.1975, 1.4325 ± 0.1125 and 0.845 ± 0.0475 (%ID/g), with T/NT ratio of 2.353 ± 0.091, 2.489 ± 0.1541 and 2.308 ± 0.1631. Here, TLR5 is linked to neoplasm.